Lupin partners with Exeltis for marketing its specialty drug Solosec in US.
Drug maker Lupin said it has entered into an agreement with Exeltis USA to promote the former’s specialty antibacterial drug Solosec in the US market. Exeltis will market Solosec along with its existing line of women’s health products, further enhancing value to OBGYNs and their patients. ET reported in October about Lupin trying to find a marketing partner or even be open to the idea of possible sale of its key specialty drug Solosec in the US.
Solosec is indicated for the treatment of bacterial vaginosis in adult women (a common vaginal infection) and trichomoniasis – a common sexually transmitted infection in adults. “This partnership will expand the reach of Solosec, allowing more healthcare providers to be aware of the benefits of Solosec, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis,” said Vinita Gupta, chief executive officer of Lupin. “The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients,” said Salustiano Perez, chief executive officer of Exeltis said., Lupin’s acquired Symbiomix Therapeutics by paying $150 million in October 2017. The drug was approved by the USFDA in September 2017, with a 10-year marketing exclusivity. Lupin earlier said it will be spending $45-50 million on an annual basis on promotions, the highest ever by the Mumbai-based drugmaker on any single drug. Lupin was earlier expecting the drug to break even by FY22, but things didn’t pan out as estimated.